Overall Survival (OS) as a Function of the Number of Therapeutic Lines in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors (WDpNET) Abstract #831

Introduction: At least 9 therapeutic options are now available for unresectable WDpNET patients. Whether all lines can be administrated before tumor or toxic-related deaths is currently unknown.
Aim(s): The primary endpoint was to determine OS as a function of the number of therapeutic lines. Secondary endpoints were to determine cumulative toxicity as defined by the frequency of modified serious adverse events (mSAE) as a function of the number of lines.
Materials and methods: Patients with unresectable WDpNET treated between 1998 and 2010 at the Gustave Roussy were studied. Locoregional (TACE) and systemic lines including somatostatin analogs or interferon[48 patients], targeted therapies (sunitinib, everolimus)[46], PRRT[26], chemotherapies (dacarbazine-, streptozotocin-, oxaliplatin-based)[82] were counted. Cumulative toxicity was defined by mSAE, including permanent toxicity (persistent grade 2-5).
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Others
Presenting Author: Amandine Berdelou
Keywords: pNets

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1471 Chemotherapy for Stage IV Sporadic Pancreatic Neuroendocrine Tumors (pNET): Are Partial Responses to Post-first Line Chemotherapy Predictable by Response/Type of First Line Chemotherapy?
Introduction: Three types of chemotherapy are recommended for stage IV pancreatic neuroendocrine tumors (pNETs): streptozocin (STZ)-, dacarbazine (DCZ)- and oxaliplatin (OX)-based. Whether cross resistance exists is unknown.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Medical Doctor Vincenzo Marotta
Authors: Marotta V, Malka D, Walter T, Do Cao C, ...
#1244 Everolimus in Progressive Metastatic Pancreatic Neuroendocrine Tumors: Analyses of Median Progression Free Survival and Safety in the Real Life Setting
Introduction: Everolimus is an oral inhibitor of mammalian target of rapamycin(mTOR) with antitumor activity in patients(pts) with pancreatic neuroendocrine tumor(pNET)s
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Michela Del Prete
#1845 Mismatch Repair (MMR) Protein Expression is Uncommon in Poorly Differentiated Neuroendocrine Carcinoma
Introduction: Microsatellite instability (MSI) has been reported to occur in a significant proportion of neuroendocrine carcinoma (NEC) and mixed adenoneuroendocrine carcinomas (MANEC) (11 out of 89 cases, Sahnane et al, ERC 2015). It might be predictive of response to immunotherapy.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Dr Julien Hadoux
#1537 Antitumor Efficacy of Temozolomide in Patients with Metastatic Pulmonary Carcinoids
Introduction: Temodal (TMZ) is an oral alternative to dacarbazine.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Diana Bello Roufai
#1922 Comparison of Long Terms Outcomes after Resection of Hepatic and /or Peritoneal Metastasis from Neuroendocrine Tumors
Introduction: The complete resection of liver metastasis LM is usually recommended in patients with grade 1-2 NET. The exact benefit of resection of peritoneal metastasis PM is unknown.
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: LĂ©onor Benhaim
Authors: Benhaim L, Faron M, Gelli M, Boige V, ...
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss out any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team